Ryboquin

Ryboquin is a Scottish biotechnology company specializing in the development of gene therapies and RNA-based medicines. The company's core focus is on overcoming the delivery challenges of genetic material using its proprietary LipTide platform, which was acquired through its merger with Nanogenics. Its lead candidate, RQN-01, is an antisense oligonucleotide targeting the EIF4E gene to sensitize cancer cells to chemotherapy. Ryboquin aims to treat a variety of conditions, including solid tumors and respiratory viral infections like COVID-19. The company operates as a private entity and has transitioned much of its public-facing identity to the Nanogenics brand following the 2021 acquisition.